Coagulation and Fibrinolytic Activity of Cerebrospinal Fluid

Overview

Journal J Clin Pathol

Specialty Pathology

Date 1978 May 1

PMID 649775

Citations 15

Authors

M Anderson

K B Matthews

J Stuart

Affiliations

Soon will be listed here.

Abstract

Fibrin/fibrinogen degradation products (fragments D and E) were detected in cerebrospinal fluid in 23.4% of 252 patients admitted to a neurological/neurosurgical unit. Other coagulation proteins of low molecular weight (plasminogen and factor IX) were also present but larger proteins (fibrinogen and factor V) were not. These findings are consistent with protein leakage across a blood-CSF barrier damaged by inflammatory, vascular, or neoplastic disease. Fibrin/fibrinogen degradation products in cerebrospinal fluid after subarachnoid haemorrhage may not, therefore, be a reliable index of increased fibrinolytic activity in the subarachnoid space and may be misleading when selecting patients for fibrinolytic blockade.

Citing Articles

Analysis of CSF D-Dimer to Identify Intrathecal Fibrin-Driven Autoimmunity in Patients With Multiple Sclerosis.

Schaller-Paule M, Yalachkov Y, Steinmetz H, Friedauer L, Hattingen E, Miesbach W Neurol Neuroimmunol Neuroinflamm. 2022; 9(3).

PMID: 35260469 PMC: 8906189. DOI: 10.1212/NXI.0000000000001150.

Metformin as a Potential Agent in the Treatment of Multiple Sclerosis.

Dziedzic A, Saluk-Bijak J, Miller E, Bijak M Int J Mol Sci. 2020; 21(17).

PMID: 32825027 PMC: 7503488. DOI: 10.3390/ijms21175957.

Coagulation Pathways in Neurological Diseases: Multiple Sclerosis.

Ziliotto N, Bernardi F, Jakimovski D, Zivadinov R Front Neurol. 2019; 10:409.

PMID: 31068896 PMC: 6491577. DOI: 10.3389/fneur.2019.00409.

Variations in the cerebrospinal fluid proteome following traumatic brain injury and subarachnoid hemorrhage.

Connor Jr D, Chaitanya G, Chittiboina P, McCarthy P, Scott L, Schrott L Pathophysiology. 2017; 24(3):169-183.

PMID: 28549769 PMC: 7303909. DOI: 10.1016/j.pathophys.2017.04.003.

Progesterone administration modulates cortical TLR4/NF-κB signaling pathway after subarachnoid hemorrhage in male rats.

Wang Z, Zuo G, Shi X, Zhang J, Fang Q, Chen G Mediators Inflamm. 2011; 2011:848309.

PMID: 21403869 PMC: 3051156. DOI: 10.1155/2011/848309.

References

Newman R, STEWART G . THE USE OF FIBRINOLYTIC ACTIVATORS IN MENINGITIS AND SIMILAR CONDITIONS. Arch Dis Child. 1965; 40:235-42. PMC: 2019399. DOI: 10.1136/adc.40.211.235. View

STEWART G . FIBRINOLYTIC THERAPY IN MENINGITIS AND VENTRICULITIS. J Clin Pathol. 1964; 17:355-9. PMC: 480770. DOI: 10.1136/jcp.17.3.355. View

MEULEMANS O . Determination of total protein in spinal fluid with sulphosalicylic acid and trichloroacetic acid. Clin Chim Acta. 1960; 5:757-61. DOI: 10.1016/0009-8981(60)90020-6. View

Wolf P . A modification for routine laboratory use of Stefanini's method of estimating factor V activity in human oxalated plasma. J Clin Pathol. 1953; 6(1):34-8. PMC: 1023527. DOI: 10.1136/jcp.6.1.34. View

ASTRUP T, Mullertz S . The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys. 1952; 40(2):346-51. DOI: 10.1016/0003-9861(52)90121-5. View

ASTEDT B, Adielsson G, Mattsson W . Fibrin/fibrinogen degradation products in pleural exudate. Lancet. 1976; 2(7982):414. DOI: 10.1016/s0140-6736(76)92424-7. View

Whittle H, Greenwood B . Cerebrospinal fluid immunoglobulins and complement in meningococcal meningitis. J Clin Pathol. 1977; 30(8):720-2. PMC: 476532. DOI: 10.1136/jcp.30.8.720. View

Donati M, Semeraro N, Vermylen J . Detection of fibrinogen antigens with two latex techniques applied to urine concentrates. J Clin Pathol. 1973; 26(10):760-3. PMC: 477877. DOI: 10.1136/jcp.26.10.760. View

Schliep G, FELGENHAUER K . The alpha2-macroglobulin level in cerebrospinal fluid; a parameter for the condition of the blood-CSF barrier. J Neurol. 1974; 207(3):171-81. DOI: 10.1007/BF00312558. View

10.

Hunter R, Thomson T, Reynolds C, Pitcher P . Fibrin-fibrinogen degradation products in cerebrospinal fluid of patients admitted to a psychiatric unit. J Neurol Neurosurg Psychiatry. 1974; 37(3):249-51. PMC: 494636. DOI: 10.1136/jnnp.37.3.249. View

11.

Ransohoff J, GOODGOLD A, Benjamin M . Preoperative management of patients with ruptured intracranial aneurysms. J Neurosurg. 1972; 36(5):525-30. DOI: 10.3171/jns.1972.36.5.0525. View

12.

Wu K, JACOBSEN C, HOAK J . Plasminogen in normal and abnormal human cerebrospinal fluid. Arch Neurol. 1973; 28(1):64-6. DOI: 10.1001/archneur.1973.00490190082012. View

13.

Smith R, Upchurch J . Monitoring antifibrinolytic therapy in subarachnoid hemorrhage. J Neurosurg. 1973; 38(3):339-44. DOI: 10.3171/jns.1973.38.3.0339. View

14.

Tovi D, Nilsson I, THULIN C . Fibrinolysis and subarachnoid haemorrhage. Inhibitory effect of tranexamic acid. A clinical study. Acta Neurol Scand. 1972; 48(4):393-402. DOI: 10.1111/j.1600-0404.1972.tb07561.x. View

15.

Mullan S, Dawley J . Antifibrinolytic therapy for intracranial aneurysms. J Neurosurg. 1968; 28(1):21-3. DOI: 10.3171/jns.1968.28.1.0021. View

16.

Sengupta R, So S, Villarejo-Ortega F . Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms. J Neurosurg. 1976; 44(4):479-84. DOI: 10.3171/jns.1976.44.4.0479. View

17.

NIBBELINK D, Torner J, Henderson W . Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke. 1975; 6(6):622-9. DOI: 10.1161/01.str.6.6.622. View

18.

Svanberg L, ASTEDT B . Coagulative and fibrinolytic properties of ascitic fluid associated with ovarian tumors. Cancer. 1975; 35(5):1382-7. DOI: 10.1002/1097-0142(197505)35:5<1382::aid-cncr2820350522>3.0.co;2-0. View

19.

Brueton M, Tugwell P, Whittle H, Greenwood B . Fibrin degradation products in the serum and cerebrospinal fluid of patients with group A meningococcal meningitis. J Clin Pathol. 1974; 27(5):402-4. PMC: 478135. DOI: 10.1136/jcp.27.5.402. View

20.

Naish P, Evans D, PETERS D . Urinary fibrinogen derivative excretion and intraglomerular fibrin deposition in glomerulonephritis. Br Med J. 1974; 1(5907):544-6. PMC: 1633662. DOI: 10.1136/bmj.1.5907.544. View